Hutchins Gary D, Miller Michael A, Soon Victor C, Receveur Timothy
Department of Radiology, Indiana University School of Medicine, Indianapolis, IN 46202-5181, USA.
ILAR J. 2008;49(1):54-65. doi: 10.1093/ilar.49.1.54.
Positron emission tomography (PET) is well established as an important research and clinical molecular imaging modality. Although the size differences between humans and rodents create formidable challenges for the application of PET imaging in small animals, advances in technology over the past several years have enabled the translation of this imaging modality to preclinical applications. In this article we discuss the basic principles of PET instrumentation and radiopharmaceuticals, and examine the key factors responsible for the qualitative and quantitative imaging capabilities of small animal PET systems. We describe the criteria that PET imaging agents must meet, and provide examples of small animal PET imaging to give the reader a broad perspective on the capabilities and limitations of this evolving technology. A crucial driver for future advances in PET imaging is the availability of molecular imaging probes labeled with positron-emitting radionuclides. The strong translational science potential of small animal and human PET holds great promise to dramatically advance our understanding of human disease. The assessment of molecular and functional processes using imaging agents as either direct or surrogate biomarkers will ultimately enable the characterization of disease expression in individual patients and thus facilitate tailored treatment plans that can be monitored for their effectiveness in each subject.
正电子发射断层扫描(PET)作为一种重要的研究和临床分子成像方式已得到广泛认可。尽管人类与啮齿动物在体型上的差异给PET成像在小动物中的应用带来了巨大挑战,但过去几年技术的进步已使这种成像方式能够应用于临床前研究。在本文中,我们讨论了PET仪器和放射性药物的基本原理,并探讨了影响小动物PET系统定性和定量成像能力的关键因素。我们描述了PET成像剂必须满足的标准,并提供了小动物PET成像的示例,以使读者对这项不断发展的技术的能力和局限性有更全面的了解。PET成像未来发展的一个关键驱动力是可获得用发射正电子放射性核素标记的分子成像探针。小动物和人类PET强大的转化科学潜力有望极大地推动我们对人类疾病的理解。使用成像剂作为直接或替代生物标志物来评估分子和功能过程,最终将能够在个体患者中表征疾病表现,从而促进可针对每个受试者监测其有效性的个性化治疗方案的制定。